Source link : https://www.newshealth.biz/health-news/fda-oks-adjuvant-ribociclib-in-earlier-stage-breast-cancer/
The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with HR-positive, HER2-negative stages II and III breast cancer at high-risk for recurrence following surgery. FDA also approved ribociclib and the aromatase inhibitor letrozole packaged together (Kisqali Femara Co-Pack, Novartis) for the same indication. A […]
Author : News Health
Publish date : 2024-09-19 10:50:56
Copyright for syndicated content belongs to the linked Source.
Categories